Critical Study On Anubandhya- Anubandh Siddhanta AndManagement of Metabolic Manifestations due to RasDushti in Primary Hypothyroidism patients in purview ofPradhaanaprashame prashamoashamyatastathaa - NI

All India institute of Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•1. Patient taking low dose of conventional medicine (up to 50 mcg) (Stratification as per dose will be done to observe the effect in different doses of conventional medicine i.e. thyroxine).
•2. Adults of age group 18 to 50 year irrespective of race, gender, religion, caste, occupation, education.
•3. Patients who are willing to give written consent.
•4. Patients with 1 year of chronicity of disease (including recurrence).
•5. Patients with classical signs and symptoms of disease. (as per ICD 10 E03.9) [Decreased basal metabolic rate, fatigue and lethargy, sensitivity to cold, and menstrual disturbances; untreated it progresses to myxedema weight gain, constipation and dry skin.]

•1. Patients who are under high dose (i.e. 75mcg or more) of Conventional Medications because those patients may need additional intervention along with the trial drug to achieve satisfactory result in short duration of trial.
•2. Individuals with other comorbidities like hypertension, diabetes mellitus, epilepsy, tuberculosis, carcinoma, and any other severe illness.
•3. Patients with thyroiditis and postoperative Primary hypothyroidism.
•4. Pregnant , postpartum and lactating women.
•5. Individuals who have undergone Panchakarma procedures.

发起方